By Josh BeckermanAptose Biosciences shares rose 11% to $6.15 after the cancer-focused drug company presented clinical trial data for tuspetinib. The company said Saturday that tuspetinib demonstrated a favorable safety profile and delivered monotherapy responses across four dose levels.

Source: Wall Street Journal June 13, 2023 03:46 UTC